Introduction

Multiple myeloma (MM) is a neoplastic proliferation of plasma cells that usually is treated with various chemotherapy regimens, including immunomodulatory drugs. Lenalidomide (Revlimid, Celgene Corporation, Summit, NJ), an immunomodulatory agent approved by the US Food and Drug Administration (FDA) in 2006 for treatment of MM, is associated with the development of secondary cancers. The FDA issued a statement in 2012 about the increased risk with lenalidomide treatment of the following secondary primary malignancies: Acute myelogenous leukemia, myelodysplastic syndromes, and Hodgkin lymphoma. The statement did not mention glioblastoma multiforme, a Grade 4 astrocytoma, or other high-grade astrocytomas that have been reported on rare occasions in the setting of multiple myeloma.

Case Presentation

A 72-year-old man, who had been in complete remission from multiple myeloma for 1 year after treatment that included lenalidomide, presented with confusion, headache, nausea and vomiting, and recurrent falls. A magnetic resonance image of his brain revealed a mass that on stereotactic biopsy was found to be glioblastoma multiforme.

Discussion:

We present the seventh reported case of high-grade astrocytoma as a second primary malignancy in multiple myeloma and the first reported occurrence of glioblastoma multiforme after the use of lenalidomide in multiple myeloma. This report adds to the pool of cases that reveal associations between use of lenalidomide and increased risk of developing secondary primary high-grade astrocytomas in multiple myeloma.

INTRODUCTION

Multiple myeloma (MM) is a neoplastic proliferation of plasma cells that usually is treated with various chemotherapy regimens, including immunomodulatory drugs. Lenalidomide (Revlimid, Celgene Corporation, Summit, NJ), an immunomodulatory agent approved by the US Food and Drug Administration (FDA) in 2006 for treatment of MM, is associated with the development of secondary cancers. The FDA issued a statement in 2012 about the increased risk with lenalidomide treatment of the following secondary primary malignancies (SPMs) in patients with newly diagnosed MM who received lenalidomide. However, the FDA statement did not include glioblastoma multiforme (GBM), a Grade 4 astrocytoma with a poor prognosis, or other high-grade astrocytomas. Here we present a rare case of a patient with MM who was treated with lenalidomide and in whom GBM developed as an SPM. We also present a literature review of GBM and high-grade astrocytomas occurring as the SPM in MM.

CASE PRESENTATION

Presenting Concerns

A 72-year-old man presented to our hospital with 6-weeks of confusion, headache, nausea and vomiting, and recurrent falls. His medical history was remarkable for diabetes mellitus, hypertension, and insulin-dependent diabetes mellitus. He denied use of tobacco, alcohol, or illicit drugs. His family history was notable for diabetes mellitus and hypertension.

On presentation, his vital signs were normal. The patient was alert but not oriented. He had expressive aphasia, unsteady gait, and masked facies.

Biochemical and hematologic investigations yielded normal results apart from the following values: Glucose 108 mg/dL (reference range = 70-99 mg/dL), total protein 5.4 mg/dL (6.4-8.3 mg/dL), albumin 3.0 mg/dL (3.5-5.2 mg/dL), mean corpuscular volume 104.6 fL (80-100 fL), platelets 83 × 10^9/L (150-450 × 10^9/L), and vitamin B₁₂ above 1500 pg/mL (211-911 pg/mL).

Magnetic resonance imaging of the brain with and without contrast enhancement revealed a heterogeneous mass (4.9 × 4.5 × 6 cm³) in the left temporal lobe extending into the uncus and causing a mild mass effect on the midbrain.
surrounded by vasogenic edema, which caused a mass effect on the midbrain (Figure 1). Stereotactic biopsy of the mass revealed GBM, a World Health Organization Grade 4 fibrillary astrocytoma. Immunohistochemical staining was negative for isocitrate dehydrogenase 1 but positive for glial fibrillary acidic protein and p53 (Figure 2).

**Therapeutic Intervention and Treatment**

Dexamethasone and levetiracetam were given to decrease the vasogenic edema and for seizure prophylaxis, respectively. We sought the opinion of a neurosurgeon, who advised forgoing complete tumor resection because the location in the dominant temporal lobe and the presence of aphasia made the procedure too risky. Repeated brain imaging after biopsy showed development of a communicating hydrocephalus, for which a ventriculostomy shunt was placed. Within 48 hours of shunt placement, the patient’s mental status improved and his symptoms of headache and nausea/vomiting resolved.

During the next 4 weeks, the patient received 10 sessions of palliative whole-brain radiation therapy at 30 Gy to 40 Gy.

**Follow-up and Outcomes**

Our patient’s clinical status deteriorated, and his power of attorney opted for hospice care. He died four months later because of complications secondary to hospital-associated pneumonia. Table 1 shows a timeline of the case.

**DISCUSSION**

Multiple myeloma is a neoplastic proliferation of plasma cells producing a monoclonal gammopathy with related organ or tissue impairment. Newly diagnosed patients undergo induction therapy with corticosteroids plus proteasome inhibitors bortezomib or carfilzomib, thalidomide or immunomodulatory drugs lenalidomide or pomalidomide, and/or alkylating agents (eg, cyclophosphamide or melphalan), followed by autologous stem cell transplant if eligible and maintenance with thalidomide or lenalidomide and/or corticosteroids until disease progression or intolerance to treatment develops.1

Lenalidomide, a derivative of thalidomide, is an immunomodulatory drug approved by the FDA for treatment of MM in 2006.2,3 In 2012, Yang et al4 compared three Phase 3 trials examining maintenance therapy with lenalidomide vs placebo and found a nearly three-fold increase in invasive malignancies, especially hematologic malignancies, in patients with MM receiving lenalidomide. That same year, the FDA issued a warning statement about hematologic SPMs, including acute myelogenous leukemia, myelodysplastic syndromes, and Hodgkin lymphoma, after MM maintenance therapy with lenalidomide.5

One uncommon nonhematologic SPM is GBM, a Grade 4 astrocytoma. It is a solid tumor involving glial cells of the brain and is the most common primary and malignant brain tumor, in addition to the most aggressive.6 High-grade astrocytomas are extremely rare in the

---

**Table 1. Case timeline**

<table>
<thead>
<tr>
<th>Date</th>
<th>Presenting symptoms</th>
<th>Work-up (findings)</th>
<th>Treatment</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>09/2011</td>
<td>None</td>
<td>Diagnosed (asymptomatic) - light chain multiple myeloma (DS Stage II, Group A; ISS, Stage 1)</td>
<td>Conservative</td>
<td>Became symptomatic</td>
</tr>
<tr>
<td>09/2013</td>
<td>Symptomatic disease</td>
<td>Re-evaluation by Medical Oncology</td>
<td>Induction therapy with 4 cycles of bortezomib, lenalidomide, and low-dose dexamethasone; Autologous stem cell transplant; maintenance therapy with lenalidomide</td>
<td>Symptoms improved, disease stabilized</td>
</tr>
<tr>
<td>09/2014</td>
<td>None (Medical Oncology re-evaluation)</td>
<td>Clinical remission</td>
<td>Maintenance therapy with lenalidomide</td>
<td>Asymptomatic</td>
</tr>
<tr>
<td>7/2015</td>
<td>Symptoms: Confusion, headache, nausea/vomiting, and recurrent falls</td>
<td>none</td>
<td>Conservative</td>
<td>Symptoms progressed</td>
</tr>
<tr>
<td>09/2015-10/2015</td>
<td>Worsening of symptoms, hematologic abnormalities</td>
<td>MRI of head (large mass involving left temporal lobe with edema and midline shift)</td>
<td>Admission to hospital for dexamethasone and stereotactic biopsy (Grade IV fibrillary astrocytoma: Glioblastoma multiforme); ventriculostomy shunt from neurosurgery; whole-brain palliative radiation therapy (10 fractions of 30 Gy-40 Gy) from radiation oncology</td>
<td>Symptoms improved after shunt placement and radiation therapy</td>
</tr>
<tr>
<td>10/2015</td>
<td>Clinical deterioration with dyspnea</td>
<td>Chest X-ray (hospital-associated pneumonia)</td>
<td>Power of attorney opted for hospice</td>
<td>Patient died</td>
</tr>
</tbody>
</table>

DS = Durie-Salmon Staging System; ISS = International Staging System; MRI = magnetic resonance image.
Table 2. Reported cases of high-grade astrocytoma as secondary primary tumor in patients with multiple myeloma

<table>
<thead>
<tr>
<th>Source, year</th>
<th>Patient sex, age in years</th>
<th>Multiple myeloma characteristics</th>
<th>Therapy for multiple myeloma (duration)</th>
<th>Astrocytoma (WHO grade)</th>
<th>Interval from diagnosis of multiple myeloma to astrocytoma (mo)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Han et al., 2013</td>
<td>Male, 49</td>
<td>A-light-chain predominant, 69.5% plasma cells on bone marrow biopsy</td>
<td>Bortezomib, cyclophosphamide, and dexamethasone (3 mo) followed by autologous stem cell transplant, then thalidomide (22 mo)</td>
<td>Anaplastic (3)</td>
<td>26</td>
</tr>
<tr>
<td>Kato et al., 1989</td>
<td>Male, 76</td>
<td>15% plasma cells on bone marrow biopsy</td>
<td>Melphalan, prednisone, and cyclophosphamide (2 mo)</td>
<td>Diffuse gemistocytic (2)</td>
<td>2</td>
</tr>
<tr>
<td>González Silva, 1993</td>
<td>Male, 55</td>
<td>IgD predominant, 52% plasma cells on bone marrow biopsy</td>
<td>Vincristine, melphalan, prednisone, and cyclophosphamide; vincristine, carmustine, doxorubicin, and prednisone (9 cycles for 6 months), then vincristine, doxorubicin, dexamethasone, and interferon (3 cycles)</td>
<td>Glioblastoma multiforme (4)</td>
<td>24</td>
</tr>
<tr>
<td>Sonoda et al., 1998</td>
<td>Male, 53</td>
<td>IgG predominant, 17.8% plasma cells on bone marrow biopsy</td>
<td>Melphalan and prednisone (14 d)</td>
<td>Glioblastoma multiforme (4)</td>
<td>NA (coexistence, diagnosed 14 d later)</td>
</tr>
<tr>
<td>Treto Rosal et al., 2005</td>
<td>Male, 70</td>
<td>80% plasma cells on bone marrow biopsy</td>
<td>Melphalan and prednisone (19 mo)</td>
<td>Glioblastoma multiforme (4)</td>
<td>19</td>
</tr>
</tbody>
</table>

Ig = immunoglobulin; NA = not applicable; WHO = World Health Organization.

References

Disclosure Statement
The author(s) have no conflicts of interest to disclose.

Acknowledgments
Kathleen Louden, ELS, of Louden Health Communications provided editorial assistance.

How to Cite this Article